User profiles for Mayan Gilboa

Mayan Gilboa

Infectious diseases Sheba Medical Center
Verified email at sheba.gov.il
Cited by 1287

Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron

G Regev-Yochay, T Gonen, M Gilboa… - … England Journal of …, 2022 - Mass Medical Soc
A Fourth Dose of mRNA Vaccine in Health Care Workers Health care workers in Israel were
given a fourth dose of BNT162b2 or mRNA-1273 vaccine during a period of omicron-variant …

[HTML][HTML] COVID-19 vaccination and BA. 1 breakthrough infection induce neutralising antibodies which are less efficient against BA. 4 and BA. 5 Omicron variants …

…, N Zuckerman, N Atari, N Barda, M Gilboa… - …, 2022 - eurosurveillance.org
This work evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four
Omicron variants (BA.1, BA.2, BA.4 and BA.5) in healthcare workers who had breakthrough …

Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection

M Gilboa, G Regev-Yochay, M Mandelboim… - JAMA network …, 2022 - jamanetwork.com
Importance The BNT162b2 two-dose vaccine (BioNTech/Pfizer) has high effectiveness that
wanes within several months. The third dose is effective in mounting a significant immune …

Factors associated with protection from SARS-CoV-2 omicron variant infection and disease among vaccinated health care workers in Israel

M Gilboa, T Gonen, N Barda, S Cohn… - JAMA network …, 2023 - jamanetwork.com
Importance A correlation between antibody levels and risk of infection has been demonstrated
for the wild-type, Alpha, and Delta SARS-COV-2 variants. High rates of breakthrough …

Six-month follow-up after a fourth BNT162b2 vaccine dose

M Canetti, N Barda, M Gilboa… - … England Journal of …, 2022 - Mass Medical Soc
Follow-up after a Fourth BNT162b2 Vaccine Dose Although a third vaccine dose showed an
improved and sustained level of protection as compared with a second dose, the …

Screening for Asymptomatic Clostridioides difficile Carriage Among Hospitalized Patients: A Narrative Review

M Gilboa, N Baharav, E Melzer… - Infectious Diseases and …, 2023 - Springer
Clostridioides difficile infection (CDI) has become the most common healthcare-associated
infection in the United States, with considerable morbidity, mortality, and healthcare costs. …

Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose

Y Lustig, T Gonen, L Meltzer, M Gilboa… - Nature …, 2022 - nature.com
As the effectiveness of a two-dose messenger RNA (mRNA) severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) vaccine regimen decreases with time, a third dose has …

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel …

G Regev-Yochay, Y Lustig, G Joseph, M Gilboa… - The Lancet …, 2023 - thelancet.com
Background Identifying COVID-19 correlates of protection and immunity thresholds is important
for policy makers and vaccine development. We aimed to identify correlates of protection …

Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review

M Gilboa, G Bornstein, I Ben-Zvi… - Rheumatology …, 2020 - Springer
Mayan Gilboa and Gil Bornstein equally contributed to this study and are co-first. … Mayan
Gilboa declares she has no conflict of interest. Gil Bornstein declares he has no conflict of …

Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study

M Layan, M Gilboa, T Gonen… - American Journal of …, 2022 - academic.oup.com
Several studies have characterized the effectiveness of vaccines against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. However, estimates of their impact …